HLA-S and neuroblastoma: There was a successful strategy to develop peptide-centric and single-chain antibody variable fragment (scFv)-based CARs that recognize the peptide presented by two HLAs, HLA-A∗23:01 and HLA-B∗14:02, in neuroblastoma.38